<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273388</url>
  </required_header>
  <id_info>
    <org_study_id>1230.1</org_study_id>
    <secondary_id>2005-002500-42</secondary_id>
    <nct_id>NCT02273388</nct_id>
  </id_info>
  <brief_title>BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours</brief_title>
  <official_title>An Open Phase I Single Dose Escalation Study of BI 6727 Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to identify the maximum tolerated dose (MTD) of BI&#xD;
      6727 therapy in terms of drug-related adverse events. Secondary objectives are the collection&#xD;
      of overall safety and antitumour efficacy data and the determination of the pharmacokinetic&#xD;
      profile of BI 6727.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 4, 2005</start_date>
  <completion_date type="Actual">April 6, 2021</completion_date>
  <primary_completion_date type="Actual">January 19, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum tolerated dose (MTD) as defined by dose limiting toxicity</measure>
    <time_frame>3weeks of first cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumour response to therapy</measure>
    <time_frame>assessed every 6 weeks, average time of 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>assessed every 6 weeks, average time of 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc changes in a subgroup of 14 patients treated at MTD</measure>
    <time_frame>6 weeks (two first cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic parameters: area under the curve 0-24h</measure>
    <time_frame>6 weeks(two first cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic parameters: Maximum concentration</measure>
    <time_frame>6 weeks(two first cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetic parameters: termination half life</measure>
    <time_frame>6 weeks(two first cycles)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Volasertib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 6727</intervention_name>
    <arm_group_label>Volasertib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Patients with confirmed diagnosis of advanced, non resectable and / or metastatic&#xD;
             solid tumours, who have failed conventional treatment, or for whom no therapy of&#xD;
             proven efficacy exists, or who are not amenable to established forms of treatment&#xD;
&#xD;
          2. Age 18 years or older&#xD;
&#xD;
          3. Written informed consent consistent with ICH-GCP and local legislation&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score ¿ 2&#xD;
&#xD;
          5. Recovery from CTCAE Grade 2 - 4 therapy-related toxicities from previous chemo-,&#xD;
             hormone-, immuno-, or radiotherapies (except alopecia)&#xD;
&#xD;
             The 18 additional patients recruited at the MTD must also meet the following&#xD;
             criterion:&#xD;
&#xD;
          6. Measurable tumour deposits (RECIST) by one or more techniques (CT, MRI)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Serious illness or concomitant non-oncological disease considered by the investigator&#xD;
             to be incompatible with the protocol&#xD;
&#xD;
          2. Pregnancy or breastfeeding&#xD;
&#xD;
          3. Active infectious disease or known chronic Hepatitis B/Hepatitis C infection&#xD;
&#xD;
          4. Clinical evidence of active brain or leptomeningeal disease during the past 12 months&#xD;
&#xD;
          5. Second malignancy currently requiring active therapy&#xD;
&#xD;
          6. Absolute neutrophil count less than 1500 / mm3&#xD;
&#xD;
          7. Platelet count less than 100 000 / mm3&#xD;
&#xD;
          8. Bilirubin greater than 1.5 mg / dl (&gt; 26 ¿mol / L, SI unit equivalent)&#xD;
&#xD;
          9. Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater&#xD;
             than 2.5 times the upper limit of normal (if related to liver metastases greater than&#xD;
             five times the upper limit of normal)&#xD;
&#xD;
         10. Serum creatinine greater than 1.5 mg / dl (&gt; 132 ¿mol / L, SI unit equivalent)&#xD;
&#xD;
         11. Known history of relevant QT-prolongation, e.g. long QT-syndrome&#xD;
&#xD;
         12. Women and men who are sexually active and unwilling to use a medically acceptable&#xD;
             method of contraception&#xD;
&#xD;
         13. Treatment with other investigational drugs or participation in another clinical trial&#xD;
             within the past four weeks before start of therapy or concomitantly with this trial&#xD;
             (except for present trial drug)&#xD;
&#xD;
         14. Chemo-, radio or immunotherapy within the past four weeks before start of therapy or&#xD;
             concomitantly with this trial. This restriction does not apply to steroids and&#xD;
             bisphosphonates.&#xD;
&#xD;
         15. Patients unable to comply with the protocol&#xD;
&#xD;
         16. Active alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1230.1.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.1.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
studies in products where Boehringer Ingelheim is not the license holder;&#xD;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;&#xD;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

